spironolactone has been researched along with Cardiac Hypertrophy in 55 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 7.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| "Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease." | 7.80 | Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. ( Coelho-Filho, OR; Jerosch-Herold, M; Kwong, R; Mitchell, R; Moreno, H; Neilan, TG; Shah, RV, 2014) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 7.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy." | 7.78 | Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone." | 5.32 | Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003) |
| " The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure." | 4.81 | Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. ( Funder, JW; Young, MJ, 2002) |
| " β-AR overstimulation with associated cardiac hypertrophy and increased vasoconstrictor response to phenylephrine in aorta were modeled in rats by 7-day isoproterenol treatment." | 3.83 | Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. ( Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016) |
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 3.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| "The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression." | 3.80 | AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. ( Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E, 2014) |
| "Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease." | 3.80 | Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. ( Coelho-Filho, OR; Jerosch-Herold, M; Kwong, R; Mitchell, R; Moreno, H; Neilan, TG; Shah, RV, 2014) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 3.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy." | 3.78 | Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "Long-term exposure of uninephrectomized rats to desoxycorticosterone acetate (DOCA)/salt induces cardiac fibrosis and hypertrophy through mineralocorticoid receptors (MRs)." | 3.72 | Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2003) |
| "The role of renin-angiotensin-aldosterone system in cardiac remodelling was studied in isoproterenol-induced cardiac hypertrophy in rats." | 3.71 | Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. ( Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L, 2001) |
| "Danon disease is a rare X-linked genetic disease resulting from LAMP2 mutations leading to defective lysosomal function." | 1.91 | Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy. ( Alcalai, R; Arad, M; Guetta, T; Hochhauser, E; Kornowski, R; Ofek, E; Petrover, Z; Seidman, CE; Seidman, J; Yadin, D, 2023) |
| "Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses." | 1.40 | Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. ( Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W, 2014) |
| "Rosiglitazone treatment induced volume expansion and CH in wild-type and PPARγ heterozygous knockout (Pparg(+/-)) mice, but not in mice defective for ligand binding (Pparg(P465L/+))." | 1.40 | Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. ( Chang, CS; Chen, JY; Ho, LC; Maeda, N; Pandya, K; Sung, JM; Tsai, PJ; Tsai, YS, 2014) |
| " Chronic administration of a subdepressor dose of eplerenone prevented MR translocation, macrophage infiltration, myocardial fibrosis, cardiac hypertrophy, and LV dysfunction, while not affecting BPV." | 1.39 | Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats. ( Anegawa, T; Hirooka, Y; Imaizumi, T; Kage, M; Kai, H; Kajimoto, H; Koga, M; Kudo, H; Mifune, H; Miyamoto, T; Takayama, N; Yasuoka, S, 2013) |
| "In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3." | 1.39 | Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. ( Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM, 2013) |
| "Spironolactone treatment decreased the total heart weight." | 1.38 | Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2012) |
| "Hypertension is well known to increase atrial fibrillation (AF) and the development of AF is associated with atrial chamber remodeling." | 1.37 | Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. ( Aizawa, Y; Chinushi, M; Ding, L; Hanawa, H; Hoyano, M; Ito, M; Kimura, S; Kodama, M; Obata, H; Tomita, M, 2011) |
| "Cardiac hypertrophy was increased 10% by using ND and 17% by ND plus training (P < 0." | 1.37 | Anabolic steroid associated to physical training induces deleterious cardiac effects. ( Barretti, D; Da Silva, ND; de Oliveira, EM; Do Carmo, EC; Fernandes, T; Irigoyen, MC; Koike, D; Mattos, KC; Melo, SF; Rosa, KT; Wichi, RB, 2011) |
| "High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone." | 1.32 | Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Spironolactone prevented cardiac hypertrophy in adrenalectomized SHRSP." | 1.31 | Cardiac aldosterone production in genetically hypertensive rats. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000) |
| "Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions." | 1.31 | Treatment of heart failure: state of the art and prospectives. ( Greenberg, B, 2001) |
| "Myocardial fibrosis is an important determinant of pathological hypertrophy." | 1.28 | Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.09) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 23 (41.82) | 29.6817 |
| 2010's | 23 (41.82) | 24.3611 |
| 2020's | 3 (5.45) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Yadin, D | 1 |
| Guetta, T | 1 |
| Petrover, Z | 1 |
| Alcalai, R | 1 |
| Seidman, J | 1 |
| Seidman, CE | 1 |
| Ofek, E | 1 |
| Kornowski, R | 1 |
| Hochhauser, E | 1 |
| Arad, M | 1 |
| Kutsche, HS | 1 |
| Schreckenberg, R | 1 |
| Weber, M | 1 |
| Hirschhäuser, C | 1 |
| Rohrbach, S | 1 |
| Li, L | 1 |
| Niemann, B | 1 |
| Schulz, R | 1 |
| Schlüter, KD | 1 |
| Slavic, S | 1 |
| Ford, K | 1 |
| Modert, M | 1 |
| Becirovic, A | 1 |
| Handschuh, S | 1 |
| Baierl, A | 1 |
| Katica, N | 1 |
| Zeitz, U | 1 |
| Erben, RG | 1 |
| Andrukhova, O | 1 |
| Yasuoka, S | 1 |
| Kai, H | 1 |
| Kajimoto, H | 1 |
| Kudo, H | 1 |
| Takayama, N | 1 |
| Anegawa, T | 1 |
| Koga, M | 1 |
| Miyamoto, T | 1 |
| Mifune, H | 1 |
| Kage, M | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 1 |
| Marques-Neto, SR | 1 |
| Ferraz, EB | 1 |
| Rodrigues, DC | 1 |
| Njaine, B | 1 |
| Rondinelli, E | 1 |
| Campos de Carvalho, AC | 1 |
| Nascimento, JH | 1 |
| Ramírez, E | 1 |
| Klett-Mingo, M | 1 |
| Ares-Carrasco, S | 1 |
| Picatoste, B | 1 |
| Ferrarini, A | 1 |
| Rupérez, FJ | 1 |
| Caro-Vadillo, A | 1 |
| Barbas, C | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, Ó | 1 |
| Chang, CS | 1 |
| Tsai, PJ | 1 |
| Sung, JM | 1 |
| Chen, JY | 1 |
| Ho, LC | 1 |
| Pandya, K | 1 |
| Maeda, N | 1 |
| Tsai, YS | 1 |
| Kolkhof, P | 2 |
| Delbeck, M | 1 |
| Kretschmer, A | 1 |
| Steinke, W | 1 |
| Hartmann, E | 1 |
| Bärfacker, L | 1 |
| Eitner, F | 1 |
| Albrecht-Küpper, B | 1 |
| Schäfer, S | 1 |
| Coelho-Filho, OR | 1 |
| Shah, RV | 1 |
| Neilan, TG | 1 |
| Mitchell, R | 1 |
| Moreno, H | 1 |
| Kwong, R | 1 |
| Jerosch-Herold, M | 1 |
| Bostick, B | 1 |
| Habibi, J | 3 |
| DeMarco, VG | 2 |
| Jia, G | 1 |
| Domeier, TL | 1 |
| Lambert, MD | 1 |
| Aroor, AR | 1 |
| Nistala, R | 1 |
| Bender, SB | 1 |
| Garro, M | 1 |
| Hayden, MR | 2 |
| Ma, L | 2 |
| Manrique, C | 1 |
| Sowers, JR | 3 |
| Grune, J | 1 |
| Benz, V | 1 |
| Brix, S | 1 |
| Salatzki, J | 1 |
| Blumrich, A | 1 |
| Höft, B | 1 |
| Klopfleisch, R | 1 |
| Foryst-Ludwig, A | 1 |
| Kintscher, U | 1 |
| Victorio, JA | 1 |
| Clerici, SP | 1 |
| Palacios, R | 1 |
| Alonso, MJ | 1 |
| Vassallo, DV | 1 |
| Jaffe, IZ | 1 |
| Rossoni, LV | 2 |
| Davel, AP | 2 |
| Okoshi, MP | 1 |
| Cezar, MDM | 1 |
| Iyomasa, RM | 1 |
| Silva, MB | 1 |
| Costa, LCO | 1 |
| Martinez, PF | 1 |
| Campos, DHS | 1 |
| Damatto, RL | 1 |
| Minicucci, MF | 1 |
| Cicogna, AC | 1 |
| Okoshi, K | 1 |
| Michea, L | 1 |
| Villagrán, A | 1 |
| Urzúa, A | 1 |
| Kuntsmann, S | 1 |
| Venegas, P | 1 |
| Carrasco, L | 1 |
| Gonzalez, M | 1 |
| Marusic, ET | 1 |
| Qu, J | 1 |
| Volpicelli, FM | 1 |
| Garcia, LI | 1 |
| Sandeep, N | 1 |
| Zhang, J | 1 |
| Márquez-Rosado, L | 1 |
| Lampe, PD | 1 |
| Fishman, GI | 1 |
| Trzaska, E | 1 |
| Gumułka, W | 1 |
| Makulska-Nowak, HE | 1 |
| Martinez, FA | 1 |
| Pulakat, L | 1 |
| Rainey, WE | 1 |
| Whaley-Connell, AT | 1 |
| Kimura, S | 1 |
| Ito, M | 1 |
| Tomita, M | 1 |
| Hoyano, M | 1 |
| Obata, H | 1 |
| Ding, L | 1 |
| Chinushi, M | 1 |
| Hanawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Do Carmo, EC | 1 |
| Fernandes, T | 1 |
| Koike, D | 1 |
| Da Silva, ND | 1 |
| Mattos, KC | 1 |
| Rosa, KT | 1 |
| Barretti, D | 1 |
| Melo, SF | 1 |
| Wichi, RB | 1 |
| Irigoyen, MC | 1 |
| de Oliveira, EM | 1 |
| Mesripour, A | 1 |
| Iyer, A | 1 |
| Brown, L | 1 |
| Martín-Fernández, B | 1 |
| de las Heras, N | 1 |
| Miana, M | 1 |
| Ballesteros, S | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Cachofeiro, V | 1 |
| Lahera, V | 1 |
| Yoneda, T | 3 |
| Demura, M | 2 |
| Takata, H | 2 |
| Kometani, M | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 2 |
| Takeda, Y | 3 |
| Goyal, BR | 1 |
| Mehta, AA | 1 |
| Moura, LM | 1 |
| Rocha-Gonçalves, F | 1 |
| Emery, RW | 1 |
| Pai, AD | 1 |
| Pai, RG | 1 |
| Zendaoui, A | 1 |
| Lachance, D | 1 |
| Roussel, E | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Al-Mazroua, HA | 1 |
| Al-Rasheed, NM | 1 |
| Korashy, HM | 1 |
| Young, MJ | 3 |
| Funder, JW | 6 |
| Moussa, L | 1 |
| Dilley, R | 1 |
| Fujisawa, G | 1 |
| Okada, K | 1 |
| Muto, S | 1 |
| Fujita, N | 1 |
| Itabashi, N | 1 |
| Kusano, E | 1 |
| Ishibashi, S | 1 |
| Lal, A | 1 |
| Veinot, JP | 1 |
| Leenen, FH | 1 |
| Qin, W | 1 |
| Rudolph, AE | 1 |
| Bond, BR | 1 |
| Rocha, R | 1 |
| Blomme, EA | 1 |
| Goellner, JJ | 1 |
| McMahon, EG | 1 |
| JOHNSTON, LC | 1 |
| GRIEBLE, HG | 1 |
| SCHOENBERGER, JA | 1 |
| FULLER, JB | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Matsui, Y | 1 |
| Jia, N | 1 |
| Okamoto, H | 1 |
| Kon, S | 1 |
| Onozuka, H | 1 |
| Akino, M | 1 |
| Liu, L | 1 |
| Morimoto, J | 1 |
| Rittling, SR | 1 |
| Denhardt, D | 1 |
| Kitabatake, A | 1 |
| Uede, T | 1 |
| Karram, T | 1 |
| Abbasi, A | 1 |
| Keidar, S | 1 |
| Golomb, E | 1 |
| Hochberg, I | 1 |
| Winaver, J | 1 |
| Hoffman, A | 1 |
| Abassi, Z | 1 |
| Cordaillat, M | 1 |
| Rugale, C | 1 |
| Casellas, D | 1 |
| Mimran, A | 1 |
| Jover, B | 1 |
| Nagata, K | 1 |
| Obata, K | 1 |
| Xu, J | 1 |
| Ichihara, S | 1 |
| Noda, A | 1 |
| Kimata, H | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Franco, V | 1 |
| Chen, YF | 1 |
| Feng, JA | 1 |
| Li, P | 1 |
| Wang, D | 1 |
| Hasan, E | 1 |
| Oparil, S | 1 |
| Perry, GJ | 1 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Abe, Y | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Stas, S | 1 |
| Whaley-Connell, A | 1 |
| Appesh, L | 1 |
| Karuparthi, PR | 1 |
| Qazi, M | 1 |
| Morris, EM | 1 |
| Cooper, SA | 1 |
| Link, CD | 1 |
| Stump, C | 1 |
| Hay, M | 1 |
| Ferrario, C | 1 |
| Rickard, AJ | 1 |
| Morgan, J | 1 |
| Fuller, PJ | 1 |
| Zhu, A | 1 |
| Usukura, M | 1 |
| Schreiber, V | 1 |
| Stĕpan, J | 1 |
| Kölbel, F | 1 |
| Pribyl, T | 1 |
| Jahodová, J | 1 |
| Kubová, V | 1 |
| Miyamori, I | 1 |
| Mabuchi, H | 1 |
| Gallego, M | 1 |
| Espiña, L | 1 |
| Vegas, L | 1 |
| Echevarria, E | 1 |
| Iriarte, MM | 1 |
| Casis, O | 1 |
| Greenberg, B | 1 |
| Ehrlich, U | 1 |
| Klepzig, H | 1 |
| Wilkins, GE | 1 |
| Brilla, CG | 1 |
| Weber, KT | 1 |
| Kilcoyne, MM | 1 |
| Thomson, GE | 1 |
| Branche, G | 1 |
| Williams, M | 1 |
| Garnier, C | 1 |
| Chiles, B | 1 |
| Soland, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for spironolactone and Cardiac Hypertrophy
| Article | Year |
|---|---|
[The use of aldosterone antagonists in the cardiovascular diseases].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers | 2009 |
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
52 other studies available for spironolactone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Genetic Therapy; Glycogen Storage Disease Type IIb; | 2023 |
Alterations in Glucose Metabolism During the Transition to Heart Failure: The Contribution of UCP-2.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Survival; Chronic Disease; Female; Glucose; Glucose Tran | 2020 |
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc | 2017 |
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Ep | 2013 |
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male | 2014 |
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; D | 2013 |
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
Topics: Animals; Cardiac Volume; Cardiomegaly; Diuretics; Extracellular Signal-Regulated MAP Kinases; Furose | 2014 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di | 2014 |
Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.
Topics: Animals; Cardiac Imaging Techniques; Cardiomegaly; Fibrosis; Heart; Hypertension; Magnetic Resonance | 2014 |
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
Topics: Animals; Cardiomegaly; Diastole; Diet, High-Fat; Diet, Western; Dietary Sucrose; Disease Models, Ani | 2015 |
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Eplerenone; Gene Expression; Male; Mice; Mice, Inbred | 2016 |
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; | 2016 |
Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload.
Topics: Aldosterone; Animals; Aortic Valve Stenosis; Cardiomegaly; Electrocardiography; Male; Mineralocortic | 2016 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Cardiomegaly; Disease Models, Animal; | 2008 |
Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart.
Topics: Animals; Cardiomegaly; Connexin 43; Disease Models, Animal; Diuretics; Gap Junctions; Heart Conducti | 2009 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.
Topics: Animals; Blood Pressure; Cardiomegaly; Endomyocardial Fibrosis; Male; Mineralocorticoid Receptor Ant | 2011 |
Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
Topics: Animals; Atrial Fibrillation; Cardiomegaly; Eplerenone; Fibrosis; Heart Atria; Hypertension; Male; M | 2011 |
Anabolic steroid associated to physical training induces deleterious cardiac effects.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Anabolic Agents; Angiotensin II Type 1 Receptor Blocker | 2011 |
Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Heart; Heart Ventricles; In | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Topics: Adrenal Gland Neoplasms; Adult; Aldosterone; Antihypertensive Agents; Cardiomegaly; Enalapril; Human | 2012 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazol | 2012 |
Aldosterone antagonists and chronic aortic regurgitation: promising but not quite ready for prime time.
Topics: Animals; Aortic Valve Insufficiency; Cardiomegaly; Male; Mineralocorticoid Receptor Antagonists; Spi | 2012 |
Potentially modifiable biological targets in aortic regurgitation.
Topics: Animals; Aortic Valve Insufficiency; Cardiomegaly; Male; Mineralocorticoid Receptor Antagonists; Spi | 2012 |
Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation.
Topics: Animals; Aortic Valve Insufficiency; Blood Pressure; Cardiomegaly; Chronic Disease; Diastole; Diseas | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, | 2013 |
Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Blood Pressure; Carbenoxolone; Cardiomegaly; Coronar | 2003 |
Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
Topics: Animals; Blood Pressure; Cardiomegaly; Collagen; Desoxycorticosterone; Fibrosis; Guanidines; Male; M | 2003 |
Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Diuretics; Dose-Response Relationship, | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
TREATMENT OF ARTERIAL HYPERTENSIVE DISEASE WITH DIURETICS. III. CHLORTHALIDONE ALONE AND IN COMBINATION WITH SPIRONOLACTONE.
Topics: Bendroflumethiazide; Cardiomegaly; Chlorides; Chlorthalidone; Coronary Disease; Creatine; Creatinine | 1964 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone | 2004 |
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Arteri | 2005 |
Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats.
Topics: Administration, Oral; Animals; Blood Pressure; Body Weight; Cardiomegaly; Diuretics; Drug Interactio | 2005 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corti | 2006 |
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Corticosterone; Epleren | 2006 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Topics: Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Chronic Disease; Fibrosis; Mag | 2007 |
Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
Topics: Animals; Biomarkers; Blood Pressure; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Desoxycortico | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Failure of the aldosterone antagonist spironolactone to inhibit myocardial hypertrophy produced by experimental hyperthyroidism and accompanied by "apparent" digoxin immunoreactivity in the blood.
Topics: Animals; Antigen-Antibody Reactions; Cardiomegaly; Digoxin; Heart; Hyperthyroidism; Male; Organ Size | 1980 |
Cardiac aldosterone production in genetically hypertensive rats.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardi | 2000 |
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Collagen | 2001 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; | 2001 |
[Long term therapy over nine years with Spironolacton in hydropic cardiac insufficiency].
Topics: Aged; Blood Pressure; Body Weight; Cardiac Glycosides; Cardiomegaly; Diuretics; Drug Therapy, Combin | 1976 |
Hypertension, hypokalemia, hyporeninemia and severe target organ damage.
Topics: Aldosterone; Blood Pressure; Cardiomegaly; Female; Humans; Hyperaldosteronism; Hypertension; Hypokal | 1976 |
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype | 1992 |
Characteristics of hypertension in the black population.
Topics: Adult; Angiotensin II; Animals; Black or African American; Cardiomegaly; Cerebrovascular Disorders; | 1974 |